TRENTON, N.J. (AP) – Hillary Clinton was among the patients and politicians who voiced outrage this week after it became public that the price of a 62-year-old drug used to treat a life-threatening infection had been raised by more than 5,000 percent.
But exorbitant drug price hikes like that have happened increasingly over the last few years. And they could become even more common because of decreasing competition in the pharmaceutical industry, among other factors.
The issue was brought to light after a Sunday article on drug price increases by The New York Times.
The story featured Turing Pharmaceuticals, a startup that paid Impax Laboratories $55 million in August for rights to Daraprim. It’s the only approved treatment for a rare parasitic infection called toxoplasmosis that mainly strikes pregnant women, cancer patients and AIDS patients.
Turing’s CEO, former hedge fund manager Martin Shkreli, soon raised Daraprim’s price from $13.50 to $750 per pill.
